CR10906A - "compuesto (1,2,3)- benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas" - Google Patents

"compuesto (1,2,3)- benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas"

Info

Publication number
CR10906A
CR10906A CR10906A CR10906A CR10906A CR 10906 A CR10906 A CR 10906A CR 10906 A CR10906 A CR 10906A CR 10906 A CR10906 A CR 10906A CR 10906 A CR10906 A CR 10906A
Authority
CR
Costa Rica
Prior art keywords
glutamatergical
benzotriazinona
replaced
compound
increase
Prior art date
Application number
CR10906A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR10906A publication Critical patent/CR10906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invencion se refiere a la prevencion y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en las sinapsis en las redes cerebrales responsables de comportamientos de orden superior. Estas redes cerebrales estan implicadas en las capacidades cognitivas relacionadas con la alteracion de la memoria, tal como se observa en una variedad de demencias, y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos.
CR10906A 2007-01-03 2009-07-02 "compuesto (1,2,3)- benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas" CR10906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02

Publications (1)

Publication Number Publication Date
CR10906A true CR10906A (es) 2009-10-23

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10906A CR10906A (es) 2007-01-03 2009-07-02 "compuesto (1,2,3)- benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas"

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578290A (en) * 2007-01-03 2012-03-30 Cortex Pharma Inc 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9242938B2 (en) 2011-11-22 2016-01-26 Beijing Medisan Technology Co., Ltd Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
ES2174851T3 (es) 1992-07-24 2002-11-16 Univ California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
CZ2004632A3 (cs) * 2001-11-26 2004-08-18 Cortexápharmaceuticalsźáinc Karbonylbenzoxazinové sloučeniny pro zvýšení glutamátergních synaptických odpovědí
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
EA200501117A1 (ru) * 2003-01-13 2006-02-24 Кортекс Фармасеутикалс, Инк. Способ лечения снижения когнитивной способности вследствие лишения сна и стресса
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
NZ578290A (en) 2007-01-03 2012-03-30 Cortex Pharma Inc 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
WO2008143963A1 (en) 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
KR20100063087A (ko) 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논

Also Published As

Publication number Publication date
TN2009000277A1 (en) 2010-10-18
CA2674460C (en) 2014-07-15
EP2144506A4 (en) 2010-05-05
CA2674460A1 (en) 2008-07-17
ME00819B (me) 2012-03-20
GT200900189A (es) 2011-08-02
IL199651A (en) 2015-08-31
AR064740A1 (es) 2009-04-22
EP2144506B1 (en) 2011-10-05
NI200900131A (es) 2010-03-11
US8173644B2 (en) 2012-05-08
HN2009001268A (es) 2011-12-27
AP2009004931A0 (en) 2009-08-31
AU2007342365B2 (en) 2012-11-15
DK2144506T3 (da) 2012-03-05
ES2374995T3 (es) 2012-02-23
US20100137295A1 (en) 2010-06-03
SV2009003322A (es) 2010-02-05
EA200900925A1 (ru) 2009-12-30
CY1112493T1 (el) 2015-12-09
MX2009007242A (es) 2009-09-02
JP2010514838A (ja) 2010-05-06
HK1140105A1 (en) 2010-10-08
AP2502A (en) 2012-10-23
MA31160B1 (fr) 2010-02-01
EA017437B1 (ru) 2012-12-28
NZ578293A (en) 2012-01-12
CN101616592B (zh) 2013-06-05
ZA200904826B (en) 2010-09-29
ECSP099499A (es) 2009-10-30
IL199651A0 (en) 2010-04-15
AU2007342365A1 (en) 2008-07-17
CU20090117A7 (es) 2011-10-05
ATE527269T1 (de) 2011-10-15
SG163545A1 (en) 2010-08-30
CN101616592A (zh) 2009-12-30
PT2144506E (pt) 2011-12-21
WO2008085506A1 (en) 2008-07-17
CU23804B7 (es) 2012-03-15
MY154877A (en) 2015-08-14
EP2144506A1 (en) 2010-01-20
BRPI0720749A2 (pt) 2014-01-14
HRP20110970T1 (hr) 2012-01-31
SI2144506T1 (sl) 2012-01-31
RS52108B (sr) 2012-08-31
PL2144506T3 (pl) 2012-04-30
JP5139446B2 (ja) 2013-02-06
GEP20125438B (en) 2012-03-26

Similar Documents

Publication Publication Date Title
CR10906A (es) "compuesto (1,2,3)- benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas"
CR10913A (es) Compuestos de benzotriazinone para mejorar las respuestas sinapticas glutamatergicas
JO3070B1 (ar) عوامل لمعالجة إضطرابات تتضمن تعديل مستقبلات الريانودين
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
EP2456772A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
BRPI0811581A2 (pt) Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
PL2307000T3 (pl) Połączenie pilokarpiny i metimazolu do leczenia choroby Charcota-Mariegotootha i pokrewnych zaburzeń
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
SV2010003694A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
DK2137192T3 (da) Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
EP2566856A4 (en) COMPOUNDS AND METHOD FOR TREATING BRAIN DISEASES
IT1393712B1 (it) Composizioni oftalmiche per la riepitelizzazione, la cicatrizzazione, e la disinfezione dei tessuti oculari
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
EP4316489A4 (en) Therapeutic agent for gait disturbance

Legal Events

Date Code Title Description
FC Refusal